JW (Cayman) Therapeutics Co Ltd
02126
Company Profile
Business description
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Contact
No. 699 Zhong Ke Road
5th Floor, Building B, Wison Center
Pudong New District
Shanghai
CHNT: +86 2150464201
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
314
Stocks News & Analysis
stocks
Major ASX miner reduces aluminium exposure
The Alcoa transaction unlocks value and sharpens ASX miners focus on base metals.
stocks
Vegemite owner’s shares remain expensive on normalising profits.
Australian dairy staple to see profits normalise with shares screening as overvalued.
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,037.00 | 11.20 | 0.12% |
| CAC 40 | 8,473.64 | 34.43 | -0.40% |
| DAX 40 | 25,795.03 | 15.72 | 0.06% |
| Dow JONES (US) | 52,816.07 | 84.00 | -0.16% |
| FTSE 100 | 10,630.42 | 48.61 | -0.46% |
| HKSE | 23,616.32 | 266.29 | 1.14% |
| NASDAQ | 26,125.54 | 292.87 | 1.13% |
| Nikkei 225 | 69,737.69 | 6.38 | -0.01% |
| NZX 50 Index | 13,763.10 | 144.68 | 1.06% |
| S&P 500 | 7,527.65 | 44.41 | 0.59% |
| S&P/ASX 200 | 8,831.00 | 12.70 | 0.14% |
| SSE Composite Index | 4,041.24 | 2.41 | -0.06% |